📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Biofil Chemicals Q3 Revenue Plummets 94% YoY to ₹85.63 Lakhs Amid Factory Renovation
Biofil Chemicals & Pharmaceuticals reported a severe decline in its financial performance for Q3 FY26, with revenue from operations crashing to ₹85.63 Lakhs from ₹1419.52 Lakhs in the same period last year. Net profit followed suit, dropping to ₹7.92 Lakhs compared to ₹16.46 Lakhs YoY. The company attributed this massive operational disruption to mandatory factory renovations and upgrades required to comply with the revised Schedule M of the Drugs & Cosmetics Rules. Consequently, the Chemicals division reported zero revenue for the quarter, while Pharma revenue saw a drastic reduction.
Key Highlights
Revenue from operations fell by 94% YoY to ₹85.63 Lakhs from ₹1419.52 Lakhs.
Net Profit for the quarter declined 51.9% YoY to ₹7.92 Lakhs.
Chemicals division revenue dropped to zero for the quarter compared to ₹139.61 Lakhs in the preceding quarter.
Manufacturing operations were partially disrupted due to factory renovation for Schedule M compliance.
Earnings Per Share (EPS) halved to ₹0.05 from ₹0.10 in the corresponding quarter of the previous year.
💼 Action for Investors
Investors should exercise caution as the company's core manufacturing is currently hampered by facility upgrades; monitor for updates regarding the completion of renovations and the timeline for resuming full-scale production.